Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.

Current opinion in oncology - 1 Jul 2011

Montemurro Michael, Bauer Sebastian

Abstract excerpt

PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, have changed the outcome of patients with gastrointestinal stromal tumor (GIST) and prolonged survival by many-fold. Unfortunately, treatment failure and tumor progression seem inevitable over time and constitute an unresolved clinical challenge. This article reviews current efforts to overcome drug resistance and progression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Clinical Trials as Topic
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrroles

Share to Sunitinib

Share to Treatment Failure

Source

Identifiers

PMID: 21519258
DOI: 10.1097/CCO.0b013e3283477ac2

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.PMID 21519258Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read ↗

Molecular basis and management of gastrointestinal stromal tumors.Semantic proximity Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumors.Semantic proximity Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.